How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
News Dec 22, 2014
Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.
However, glycan mapping is a complicated and multi-step process. Rapid, reproducible and high resolution glycan mapping is now achievable thanks to developments in column technology which help researchers overcome the challenges associated with glycan analysis.
One of the biggest challenges associated with glycan mapping is achieving high-resolution with fast analysis times without compromising performance. In addition to long analysis times, achieving reproducible glycan results can be another challenge because glycan analytes are often of low abundance in complex biological samples and the glycans must be cleaved from the glycoprotein and labeled prior to analysis. Instrument limitations can also be another issue due to increased levels of backpressure with the sub 2 um particles.
To help researchers overcome the challenges associated with glycan analysis, Agilent has introduced its AdvanceBio Glycan Mapping columns which have been engineered and manufactured to deliver rapid, reproducible, high-resolution glycan identification to increase throughput without sacrificing the quality of data. These innovative columns have a unique bonding which uses a HILIC mechanism to support glycan separations to achieve high speed performance. Glycan maps can now be obtained in less than ten minutes with 1.8µm particles which is a significant benefit when analyzing and characterizing a large volume of samples during process development.
To read the full story and discover how you can simplify glycan mapping for characterizing candidate biotherapeutics click here.
Immatics Enters into a Strategic Partnership with GenmabNews
Immatics and Genmab to combine proprietary technologies to create transformative bispecific therapies against novel, proprietary tumor targets.READ MORE